HC Wainwright Has Bullish Forecast for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Stock analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for REGENXBIO in a research note issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings per share of ($1.21) for the quarter, up from their previous estimate of ($1.35). HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

A number of other research firms also recently weighed in on RGNX. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Raymond James initiated coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.88.

REGENXBIO Stock Down 1.6 %

RGNX stock opened at $8.36 on Wednesday. REGENXBIO has a twelve month low of $5.62 and a twelve month high of $23.14. The company has a market cap of $414.20 million, a PE ratio of -1.66 and a beta of 1.35. The business’s 50-day simple moving average is $7.29 and its 200 day simple moving average is $8.93.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. The company had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGNX. GAMMA Investing LLC lifted its stake in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC raised its stake in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of REGENXBIO in the fourth quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd bought a new position in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Finally, Laurion Capital Management LP bought a new position in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.